卓正医疗(02677.HK)拟全球发售475万股股份 预计2月6日上市

Core Viewpoint - 卓正医疗 is planning a global offering of 4.75 million shares, targeting the high-end medical service market in China, with a focus on affluent consumers seeking personalized care [1][2]. Company Overview - 卓正医疗 is a private medical service provider in China, emphasizing high-end medical services for affluent individuals with a disposable income exceeding RMB 200,000 [1]. - The company is the third-largest private high-end medical service provider in China, holding a market share of 2.0% in the private high-end medical service sector [2]. Market Insights - The total revenue of China's private high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, with a compound annual growth rate (CAGR) of 21.9% [2]. - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2]. Fundraising and Use of Proceeds - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 90.79 million [3]. - Assuming a mid-range offer price of HKD 62.15 per share, the company estimates net proceeds of approximately HKD 219.1 million from the global offering [4]. - The intended use of proceeds includes 35% for developing a talent pool for medical AI applications, 30% for upgrading existing facilities and establishing new ones, 25% for acquiring well-performing medical institutions, and 10% for working capital [4].